Consistently, GREM1, the antagonist of BMP that signals through SMADs was highly up-regulated in mutant FLCN and FLCN-null UOK257 cells although its expression was low in BHD-associated renal tumors. The gene discussed is GREM1; the disease is kidney neoplasm.